More on 4568
News
- Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results
- Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy
- EU panel backs Enhertu plus pertuzumab for HER2+ breast cancer
- Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer
- Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors
- EU panel backs Datroway for metastatic breast cancer patients
- Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy
- Daiichi Sankyo Showcases Progress Across Industry-Leading Oncology Portfolio with Latest Research Updates at ASCO
- Daiichi Sankyo Europe Reaffirms Commitment to Patient-Centred Care with Extensive Data Showcase at EAS Congress 2026
- Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Cand
Entities mentioned with 4568
- FDA | View Related Stories »
- Twitter | View Related Stories »
- S1 | View Related Stories »
- PDUFA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Deutsche Bank | View Related Stories »
- Earnings | View Related Stories »
- ARK | View Related Stories »
- Show More...
